ABPI has published a guide for pharmaceutical companies on how to work successfully, collaboratively, and ethically with patients and patient groups, in line with the ABPI Code of Practice.
The Association of the British Pharmaceutical Industry (ABPI) has published a guide for pharmaceutical companies on how to work successfully, collaboratively, and ethically with patients and patient groups, in line with the ABPI Code of Practice.
“Working with patients and patient organizations-a sourcebook for industry” has also been published in response to patient organizations looking for greater clarity on relationships with pharma companies. Additionally, it endorses the viewpoint of ABPI that through collaboration with patients and patient organizations it is possible to gain significant public health benefits.
“The industry is here to develop medicines that address unmet medical needs, and it is clear that to understand that need, you must learn from the people living with the condition,” said Jill Pearcy, director of ABPI Code Engagement, who authored the report. “We have worked with patient organizations to produce a sourcebook which includes practical guidance, tips, and tools to support pharmaceutical companies [in collaborating] with patients and patient organizations. It might sound obvious, but if you are not working with patient interest at the heart of what you do you can’t be truly patient-centric. As an industry, we are committed to this.”
Covering six topics that were highlighted as key areas where further guidance would be useful, the sourcebook includes information on principles and agreements, definitions of patient organizations, patients or patient advocates, events and meetings, R&D, payments, and product launches.
Source: ABPI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.